{"analyses":[{"ciLowerLimit":"17.88","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"33.33","estimateComment":"95% CI for rates were constructed using Pearson- Clopper method. 95% CI for difference in rates were constructed using Anderson-Hauck method.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Difference in Response Rates","paramValue":"25.61","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"3.97","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"15.37","estimateComment":"OR was estimated using logistic regression model. The 95% CI was computed using Wald test.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"7.81"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.76","upperLimit":"12.98","value":"8.2"},{"groupId":"OG001","lowerLimit":"20.24","upperLimit":"33.07","value":"26.3"}]}],"title":"CR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.01","upperLimit":"2.82","value":"0.5"},{"groupId":"OG001","lowerLimit":"0.32","upperLimit":"4.45","value":"1.5"}]}],"title":"CRi"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.22","upperLimit":"10.50","value":"6.2"},{"groupId":"OG001","lowerLimit":"1.46","upperLimit":"7.29","value":"3.6"}]}],"title":"nPR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"45.56","upperLimit":"59.99","value":"52.8"},{"groupId":"OG001","lowerLimit":"54.62","upperLimit":"68.72","value":"61.9"}]}],"title":"PR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"194"}],"units":"Participants"}],"description":"Response was assessed by investigator according to iwCLL guidelines and was confirmed by repeat assessment \\>/=4 weeks after initial documentation. CR: peripheral blood lymphocytes \\<4000/mcL; absence of any new lesion, nodal disease, lymphadenopathy, hepatomegaly, splenomegaly, and constitutional symptoms; neutrophils \\>1500/mcL, platelets \\>100000/mcL, hemoglobin \\>11.0 g/dL without need for transfusion or exogenous growth factors; normocellular bone marrow with \\<30% lymphocytes; no lymphoid nodules. CRi: fulfilling all CR criteria but persistent cytopenia. PR: \\>/=50% reduction in two of following: peripheral blood lymphocytes, lymphadenopathy, spleen and/or liver enlargement; and 1 of following: neutrophils \\>1500/mcL, platelets \\>100000/mcL, hemoglobin \\>11.0 g/dL or \\>/=50% improvement without need for transfusion or exogenous growth factors. nPR: fulfilling all CR criteria but presence of lymphoid nodules. 95% CI was computed using Pearson-Clopper method.Percentages are rounded off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received bendamustine at a dose of 70 milligrams per meter square (mg/m\\^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG000","title":"Bendamustine + Rituximab Main Study"},{"description":"Participants were initially placed on a venetoclax ramp-up period of 5 weeks and received an initial dose of 20 mg via tablet orally once daily (QD) for initial 1 to 7 days, then venetoclax dose was incremented weekly up to a maximum dose of 400 mg, orally, QD. Participants continued receiving venetoclax at a dose of 400 mg, orally, QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to PD or 2 years, whichever occurred first, as directed by the investigator, in combination with rituximab at a dose of 375 mg/m\\^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m\\^2 on Day 1 of Cycles 2-6.","id":"OG001","title":"Venetoclax + Rituximab Main Study"}],"paramType":"NUMBER","populationDescription":"ITT population included all randomized participants, with participants grouped according to randomized treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 8 years 5 months","title":"Percentage of Participants With Best Overall Response of Complete Response (CR), CR With Incomplete Bone Marrow Recovery (CRi), Nodular Partial Response (nPR), or Partial Response (PR) as Assessed by the Investigator Using iwCLL Guidelines","type":"SECONDARY","unitOfMeasure":"percentage of participants"}